This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertexs entry into type 1 diabetes. The post Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal appeared first on MedCity News.
Introduction Weekends may be synonymous with relaxation, but for pharma marketing professionals, they offer an unmatched window to recalibrate. When deadlines arent looming and inboxes arent overflowing, theres finally time to revisit trends, read strategy insights, and uncover tools to elevate your marketing game. The Pharma Marketing Network serves as an ideal destination for this kind of weekend deep-dive.
Pharmaceutical marketing is evolving rapidly, driven by technological advancements, shifting doctor preferences, and heightened regulatory scrutiny. As we step into 2025, here are the key trends shaping the future of pharmaceutical marketing. AI-Driven Personalization in Doctor Engagement* Artificial Intelligence (AI) is transforming the way pharmaceutical brands interact with healthcare professionals (HCPs).
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
As leaders, we often talk about our teams in terms of productivity, performance, and results. But lets take a step back: how often do we define our employees as people first? In a world that emphasizes output, its easy to forget that behind every task and every deadline is a human being with unique skills, dreams, and challenges. When we recognize this, the workplace dynamic transformsimproving not only the atmosphere but also overall performance.
Isomorphic Labs financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say. The post An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 appeared first on MedCity News.
Isomorphic Labs financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say. The post An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 appeared first on MedCity News.
Introduction Social media advertising has undergone a major transformation in the pharmaceutical industry over the past decade. What once was a cautious, slow-moving experiment has now become a vital component of modern pharma marketing strategies. The increasing integration of platforms like LinkedIn, X (formerly Twitter), YouTube, and even TikTok has dramatically shifted how pharma brands engage with healthcare professionals (HCPs), patients, and caregivers.
A new industry survey from the Biotechnology Innovation Organization (BIO) highlights the vulnerability of supply that proposed tariffs would put on medicines, and its impact on patient access. According to the findings, nearly 90 percent of US biotechs rely on imported components for at least half of their products approved by the US Food and Drug Administration.
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
As the FDAs top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agencys ability to review and potentially approve such treatments. The post Ouster of Peter Marks & Mass FDA Layoffs Have Biotech Sector Bracing for Regulatory Disruptions appeared first on MedCity News.
The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.
Introduction If the past few years have taught pharma marketers anything, it’s that agility, data, and digital-first thinking aren’t just buzzwordsthey’re survival tactics. Marketing in pharma has undergone a radical shift, propelled by digital transformation, patient-centric demands, and evolving regulatory landscapes. In 2025, the strategies that succeed are rooted in personalization, innovation, and real-time adaptability.
The global pharmaceutical & biotechnology environmental monitoring market is expected to expand with a CAGR of 6.2 percent between 2025 and 2031, according a report by Lucintel. Several factors are fuelling this growth, including greater adoption of advanced innovations such as cloud technology, which are driving efficiencies and accuracy, the research highlighted.
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
By prioritizing staff education, starting small with practical applications, and establishing clear guidelines, local health departments can lay the foundation for sustainable AI adoption. This approach ultimately enhances efficiency, improves health outcomes, and ensures cost-effective care for the communities they serve. The post Bridging the AI Gap in Local Health: Practical Steps for Adoption appeared first on MedCity News.
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
Introduction Pharmaceutical marketing is entering a new era in 2025, driven by rapid advancements in technology, evolving patient expectations, and tighter compliance demands. As industry leaders adapt to digital-first communication and omnichannel engagement, the need for smart, scalable, and strategic marketing tactics is more urgent than ever. Whether you’re launching a new branded drug or optimizing an established portfolio, staying ahead of the curve in pharmaceutical marketing has be
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Artificial intelligence (AI) and Big Data are set to remain the most disruptive powers in the healthcare sector for the next two years, with Pharma executives prioritizing these innovations for the near future, according to GlobalData. 1 This report delves into some of the major obstacles and the potential for AI in the pharmaceutical industry. Register now to access exclusive content and insight from: Dr Vladimir Makarov, Programme Manager, The Pistoia Alliance Remco Jan Geukes Foppen, Vincenzo
Soleno Therapeutics Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity. The post Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug appeared first on MedCity News.
The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.
The Healthcare Businesswomens Association (HBA) has proudly announced its 2025 class of Rising Star and Luminary honorees! Nominated by the HBAs Corporate Partners, these leaders are not only exceptional contributors within their companies but also powerful advocates for health equity and women’s advancement globally, significantly contributing to the HBAs vision of Creating Women Leaders for Life.
By focusing on prevention, collaboration, and data-driven innovation, community health programs are ensuring resources are used more effectively and patient care is proactive rather than reactive. The post How Community Health Programs are Reducing 911 Calls and Helping Patients Before Emergencies appeared first on MedCity News.
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
264 
Let's personalize your content